Private healthcare market in Central Europe 2012

In Bulgaria, Slovakia, the Czech Republic, Poland and Romania, recent conditions have been favorable for the expansion of the market for private healthcare services. These events have led to increased demand by consumers for hospital care, dental and dialysis and a wide range of medical procedures, facilities and delivery systems owned and operated by private business entities. Private companies that sell health insurance and subscription programs used to pay for this medical care are on the upswing as well. The ‘Patients without borders’ directive promises to change the way Central Europeans approach healthcare, as they discover a greater choice of options and providers respond to increased competition for their services.

Private healthcare market in Central Europe 2012, Development forecasts for 2012-2014 offers a unique and comprehensive perspective on the current status and future potential of the pillars of the private healthcare industry in selected Central European countries. Composed of a series of chapters covering diverse topics from market size and value to specific segments such as insurance plans, this report delivers essential data, expert analysis and reliable forecasts to 2014.

The document tracks market growth via data on its size including value from 2008 to the present, and looks ahead with projections on the figures expected until 2014. It lists and analyses the events and trends in economics, demographics and consumer preferences and details the ways in which they are changing the marketplace, and provides updates on changes to legal statutes and regulatory requirements in force within the covered countries.

The publication pays ample attention to the expanding health insurance and medical subscriptions segments, and provides detailed corporate descriptions of the leading providers of these products and services. It examines the supply of private hospitals and health care facilities in each country and projects new investments for the forecast period. 

Prepared as a guide for professionals at work in the private healthcare sectors of Bulgaria, Slovakia, the Czech Republic, Hungary, Poland and Romania, this comprehensive report answers common questions with regard to investment possibilities in the private insurance and medical subscriptions markets, the specific drawbacks to market entry, market conditions for all segments in each country and the predicted development of each market segment during the period to 2014.

The report is an asset in the performance of a variety of business tasks, including assessing the market and preparing for entry, evaluation of investment opportunities, competition research, creating shareholder reports and estimation of revenue. It is also helpful to readers engaged in activities at government, educational and financial institutions.

Get a copy of this report @ http://www.reportsnreports.com/reports/195536-private-healthcare-market-in-central-europe-2012.html

Report Details:
Published: August 2012
No. of Pages: 279
Price:Single User License:US$3500 Corporate User License:US$8750

 

Global Epilepsy Market 2010-2014

This research has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the first-line therapies and the second-line therapies and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key questions answered in this report:

• What will the market size be in 2014 and at what rate will it grow?
• What key trends is this market subject to?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the opportunities and threats faced by each of these key vendors?
• What are the strengths and weaknesses of each of these key vendors?

2010-2014 Epilepsy Market

Published: February 2012
No. of Pages: 29
Price : Single User License - US$1500                  Corporate User License - US$2500



Table of Contents:
01. Executive Summary
02. Introduction
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Pfizer Inc.
11.2 UCB SA
11.3 GlaxoSmithKline plc.
11.4 Novartis AG
12. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Epilepsy Market 2010-2014 (US$ billion)
Exhibit 2: Global Epilepsy Market by Geographical Segmentation 2010
Exhibit 3: Global Epilepsy Market by Vendor Segmentation 2010

Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010 of Business Monitor International now available at ReportsandReports

Dallas, TX: ReportsandReports announce it will carry Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010Market Research Report in its Store.

Browse complete Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010 Report

BMI retains its robust five-year growth forecast for the Kazakhstan pharmaceutical market, with the US dollar value of the market rebounding on the back of a resurgent local currency in 2010. Our forecast sees a strong economy - driven by increasing oil and gas output and anticipated strong global prices for these exports - and appreciating currency over five-year and ten-year forecast periods. BMI calculates a compound annual growth rate (CAGR) in US dollar terms of 17.47% for 2009-2014. Full-year data for 2009 showed an 18-22% boost in market value in local terms, with a slight contraction in US dollar value.

For Kazakhstan’s bureaucrats and pharmaceutical producers, the goal is to deliver tangible increases in domestic production to meet President Nursultan Nazarbayev’s target of ensuring that 50% of medicines, in volume terms, are domestically sourced by 2014. Local production, according to the Farmmedindustriya industry association, increased by 23.4% to KZT12.4bn (US$83.7mn) in 2009. A decisive factor in supporting local output will be state purchasing. State-owned distributor SK Farmatsiya reported an increase in its share of domestically-sourced purchasing in 2009 from 8% to 23%, in volume terms. Officials say the country is on course to meet the 2014 deadline, while the country has adopted an industrial plan for the industry and a number of new production facilities are in the pipeline.

To date there has been little tangible impact from the Customs Union of Kazakhstan, Russia and Belarus launched at the beginning of 2010. BMI’s view is that the union is less important in terms of internal pharmaceutical trade - at least during the forecast period - but a significant player amid plans to harmonise market authorisation and other regulatory standards. Harmonisation, if achieved, could make these three key CIS markets easier to navigate for all players - an important development. However, some major regulatory gaps remain in Kazakhstan, such as the absence of a finalised set of local Good Manufacturing Practice (GMP) standards - despite a 2014 GMP compliance deadline - and a need to develop the country’s formulary system and link it to the Essential Drugs List.

The country’s pipeline of domestic production projects represents, potentially, the most far-reaching development for the local sector since privatisation in the 1990s and BMI estimates the value of current projects at around US$200mn, a multiple of current industry value. Crucially, many of these projects require funding from the Kazakhstan Development Bank (KDB) and National Innovation Fund, as the once-strong private banking sector has yet to recover from the global financial crisis. The furthest advanced project among locals is one by domestic champion Chimpharm to build a new tablet factory in a new industrial park in Astana. The company also has plans to expand production facilities in Shymkent. Other players, including GlobalPharm, Nobel AFF, and Romat are reportedly planning new lines or new plants. If funding can be found in the state and private sector for these projects and the country can remain politically and economically stable, Kazakhstan will have an industry capable of meeting a significant share of local needs and meeting demand in growing regional markets like Uzbekistan.

Executive Summary

SWOT Analysis

Kazakhstan Pharmaceuticals And Healthcare SWOT

Kazakhstan Political SWOT

Kazakhstan Economic SWOT

Kazakhstan - Business Environment Rating

Table: Central And Eastern Europe (CEE) Pharmaceutical And Healthcare Business Environment Ratings, Q310

Limits of Potential Returns

Risks to Realisation of Returns

Kazakhstan - Market Summary

Regulatory Regime

Intellectual Property Environment

Counterfeit Drugs

Pricing and Reimbursement Regime

Table: Price Components And Add-Ons For Imported And Locally Produced Generic Medicines (KZT)

Recent Pricing and Reimbursement Developments

Industry Developments

Epidemiology

Healthcare Sector

Table: Top 10 Manufacturers By Value Of Hospital Purchases

Table: Top 10 INNs By Value Of Hospital Purchases

Healthcare Sector Financing

Table: Top 10 ATC Groups By Value Of Hospital Purchases

Table: Top 10 ATC Groups By Retail Pharmacy Sales

Domestic Pharmaceutical Industry

Recent Domestic Industry Developments

Wholesale and Retail

Recent Wholesale and Retail Developments

Foreign Pharmaceutical Industry

Recent Foreign Industry Developments

Clinical Trials

Medical Devices

Table: Medical Devices Market In Kazakhstan, 2006-2008 (US$mn)

Industry Forecast Scenario

Overall Market Forecast

Key Growth Factors - Industry

Key Growth Factors - Macroeconomic

Table: Kazakhstan - Economic Activity

Prescription Market Forecast

OTC Market Forecast

Patented Market Forecast

Generics Market Forecast

Export/Import Market Forecasts

Other Healthcare Data Forecasts

Key Risks to BMI’s Forecast Scenario

Competitive Landscape

Table: Top 10 Manufacturers By Retail Pharmacy Sales

Table: Top 10 Trade Names By Value Of Retail Pharmacy Sales

Company Monitor

Indigenous Companies

Chimpharm

Romat FK

Foreign Companies

Novartis (Lek & Sandoz)

Sanofi-Aventis

GlaxoSmithKline (GSK)

Nycomed

Merck & Co

Pfizer

Ranbaxy

Country Snapshot: Kazakhstan Demographic Data

Section 1: Population

Table: Demographic Indicators, 2005-2030

Table: Rural/Urban Breakdown, 2005-2030

Section 2: Education and Healthcare

Table: Education, 2002-2005

Table: Vital Statistics, 2005-2030

Section 3: Labour Market and Spending Power

Table: Employment Indicators, 1999-2004

Table: Consumer Expenditure, 2000-2012 (US$)

Table: Average Annual Wages, 2000-2012

BMI Methodology

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources

Forecast Tables

Browse complete Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010 Report

Browse all Pharmaceuticals Market Research Reports

Browse all Business Monitor International Market Research Reports

Browse all Latest Report

Related Reports:

Bangladesh Pharmaceuticals and Healthcare Report Q3 2010

Chile Pharmaceuticals and Healthcare Report Q3 2010

Morocco Pharmaceuticals and Healthcare Report Q3 2010

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/